Meet the Team Behind CURLIM

Our team

Founders

Co-founder //
CEO

Laurent Richebourg
Co-founder, CEO

With over 30 years of experience in the healthcare industry, Laurent has held C-level positions across medical imaging, in-vitro diagnostics, and hospital equipment in major companies such as Abbott, Danaher, J&J and Siemens.

A graduate in biomedical engineering from the University of Technology of Compiègne (UTC) and in business from HEC, he worked closely with R&D and operations all along his career.

His numerous responsibilities in general management, marketing, sales, finance, and after-sales, at both international and national levels, have provided him with essential tools for the successful management of a company.

Franck Sturtz

Co-founder //
Steering Committee Chairman

View profile

Franck Sturtz
Co-founder, Steering Committee Chairman

Professor Sturtz is a trained neurologist, with a doctoral thesis on Charcot-Marie-Tooth disease (CMT).

After six years of research in the United States, including five at the biotech start-up Progenitor Inc., he joined the VENTECH venture capital fund as Investment Director and Partner. He later became Professor of Biochemistry and Molecular Biology.

In addition, he co-founded Medincell SA, a biotech company based in Montpellier and listed on the SBF 120 (MEDCL), with a market capitalization of approximately €450 million.

He also led the NEURIT research unit at the University of Limoges, dedicated to neuropathies and therapeutic innovation, managing a team of around 30 people.

Vincent Sol

Co-founder //
CMC Support

View profile

Vincent Sol
Co-founder, CMC Support

Professor Vincent Sol holds a PhD in science and was a visiting researcher at the University of Hull (UK).

He was appointed Professor of Organic Chemistry and served as Director of the Laboratory of Natural Substances Chemistry (EA 1069), then of the PEIRENE Laboratory at the University of Limoges, leading a team of 50 people.

He has been actively involved in technology transfer and research valorization, contributing to the creation of five start-ups backed by the laboratory.

He is also co-inventor of nine patents.

Alexis Desmoulière

Co-founder //
Pre-clinical Support

View profile

Alexis Desmoulière
Co-founder, Pre-clinical Support

Professor Desmoulière holds a PhD in Pharmacy and a State Doctorate in Science.A CNRS first-class researcher, he was appointed Professor of Physiology at the Faculty of Pharmacy at the University of Limoges.

He has led numerous industrial collaborations with major players such as Hoffmann-La Roche (Basel, Switzerland), Roche Pharma Research and Early Development, and the Roche Innovation Center Basel.

His research also includes a contract with the French Directorate General of Armaments (DGA), the RéinNERVAtion project, a partnership with Guerlain, and the ANR-funded NEUROSKIN project (2021–2024), focused on neurovascular mechanisms in rosacea using in vitro skin models (ANR-21-CE14-0027).

Operational team

Frédéric Elustondo

CTO

View profile

Frédéric Elustondo
CTO

Professor Elustondo holds a PhD in Organic Chemistry from the University of Nottingham, followed by a postdoctoral at Imperial College London – Pfizer Animal Care Unit.

He has built strong expertise in product development and team management across the biotechnology, pharmaceutical, and oncology sectors.

He notably supervised a team of 10 researchers at Cancer Research London (UK) on oncology programs, and 20 researchers at RedX Pharma (Liverpool, UK), focused on anti-infective and oncology drug development.

In France, he served as Secretary General of the Institut Bergonié (Bordeaux), and later as Director of Operations, overseeing scientific strategy, the development of a microbiotic product pipeline (LBP), and the management of operational teams across preclinical, clinical, regulatory, and CMC domains.

William Moret

Scientific Project Manager

View profile

William Moret
Scientific Project Manager

PhD in Neuroscience from the University of Limoges, with a specialization in the treatment of chemotherapy-induced peripheral neuropathies.

He brings strong expertise in the management of scientific projects — from the development of mouse models to data analysis — combined with excellent science communication skills.

He is the author of several international peer-reviewed publications and has presented his research at national and international conferences.

In 2022, he was awarded 1st place in the JEDI competition (Journées d'Échange des Doctorants autour de l'Interdisciplinarité).

Léa Juillard-Condat

Development Engineer

View profile

Léa Juillard-Condat
Development Engineer

Léa is a chemical engineer with a Master’s degree in Chemistry, specializing in Agro-resources, Biomolecules, and Innovations.

She has a multidisciplinary background in chemistry, biochemistry, microbiology, cell biology, and process engineering.

She gained solid experience through various internships and now works as a research engineer at the LABCiS laboratory for Curlim, where she is actively involved in the production of the future drug CLM001.

Dzmitry Siamashchuk

FP&A junior

View profile

Dzmitry Siamashchuk
Finance, Planning & Analysis – Junior

Dzmitry Siamashchuk holds an MBA from IAE Bordeaux (2024) and a Bachelor's degree in Finance and Banking from BDEU Minsk (2022).

He has developed international experience in France, the United States, and Belarus, with a focus on finance and business analysis.

Since May 2025, Dzmitry has been working at Curlim as Junior Analyst in Finance, Planning, and Analysis, where he is responsible for cash flow management, cost optimization, financial planning, and funding strategy.

Board

Anh Nguyen

View profile

Anh Nguyen

PhD in Molecular Biology from the University of California at San Diego (UCSD) and MBA from the Massachusetts Institute of Technology (MIT).

Co-founder of Syntro Corp., listed on Nasdaq (SYNT) in 1987 and acquired by Mallinckrodt Inc. in 1995.

Co-founder of Invitrogen Inc., listed on Nasdaq (IVGN) in 1999. The company was later acquired by Life Technologies for $2 billion, which itself was acquired by Thermo Fisher in 2013.

Co-founder of Medincell SA in 2003, now listed on the SBF 120 with a market capitalization of approximately €450 million.

Thibaut Simon

View profile

Thibaut Simon

Engineer at the CENTRALE Paris school and the Zurich Polytechnic School.Project director within an investment bank, passionate about science and technology.

Thibaut joins the general inspection of the BPCE group. He joined the Organization and Transformation teams of Natixis CIB as Project Manager, before joining the Global Market Advisory.

At the same time, he participates in several entrepreneurial projects as a founder, advisor and/or investor.

Affected by CMT since his childhood, Thibaut has in-depth knowledge of the disease and therapeutic issues.

Jean-Marc Patouillaud

View profile

Jean-Marc Patouillaud
President of CentraleSupelec Venture

MS in Engineering (CENTRALE SUPELEC) and MBA (HEC). Jean-Marc began his career at Cegelec, then joined Finovelec–Genese fund.He entered the Partech group in 1996, where he served as General Partner of the Venture fund.

Jean-Marc later became Managing Partner of the management company Partech Partners, which manages €3 billion in assets.

In addition, he is a board member of several companies and has recently led major M&A operations with La Poste (Happytal), Decathlon (Alltricks), the Altice Group (Teads), and TripAdvisor (La Fourchette).

Julie Le Moing

View profile

Julie Le Moing

Double Diploma Engineer (National School of Agronomy and Food Industrie, Nancy) and MBA (Institute of Business Administration, Nancy), Certificate of Animator in Industrial Property (National Institute of Industrial Property, France).

Julie began her career within major luxury and cosmetics groups (LVMH, PUIG). For 8 years, she managed projects with cross-functionnal missions for international brands ranging from marketing to production.

She joined the field of technology transfer in 2016 as Business Development Manager at AVRUL (Limoges, France). In charge of projects sourcing and funding, technology marketing and assesment, licencing, she managed a annual portfolio of ~100 technologies with 40 transfer agreement negociated and signed.

Get in touch

For professional inquiries regarding our research, partnerships, or investment opportunities, please reach out to us via the contact information provided on our page.